|
|
KEYNOTE PRESENTERS
|
|
|
Alan Breier,
M.D., Vice President for Medical and Chief Medical Officer, Eli
Lilly and Company |
|
Lionel
Edwards, MBBS, FFPM, Director, Medical Affairs, Novartis
Pharmaceuticals
|
|
Gary K.
Mallow, Ph.D., Director, Research Information Services, Merck &
Co., Inc.
|
|
Eleftherios
P. Diamandis, M.D., Ph.D., FRCPC, Head, Clinical Biochemistry &
Pathology, Mt. Sinai Hospital
|
|
Dennis J. Slamon, M.D., Ph.D., Chief, Division of Hematology/Oncology, David Geffen School of Medicine, UCLA, and Director Revlon/UCLA Womens Cancer Research Program, Jonsson Comprehensive Cancer Center
|
|
|
This special, two-day executive forum will show you how to optimize clinical trials through strategy, technology, process, and policy.
Scientific Advisory Board
Kenneth Evans, Ph.D., President and Chief Executive Officer, Ontario Cancer Biomarker Network
Charles Jaffe, M.D., Ph.D., Senior Global Strategist, Digital Health Group, Intel Americas, Inc.
David S. Lester, Ph.D., New York Site Head, WorldWide Clinical Technology, Pfizer Inc.
Robert Phillips, Ph.D., Chief Operating Officer, Ontario Institute for Cancer Research
Sessions
Include:
|
Generating and Managing Biomarker Data
|
|
|
|
Building an Effective and Compliant
Network for Data Sharing
|
|
|
|
Designing Trials of the Future
|
|
|
|
Pre-Conference Tutorial
|
|
|
Circulating Tumor Cells as Biomarkers and Their use in Oncology Clinical Trial Design and Drug
Development
Leon W.M.M. Terstappen, M.D., Ph.D., Senior Vice President of R&D and Chief Scientific Officer, Immunicon
|
|
|
|
|
|
Rationale for Inclusion of CTCs in Clinical Trials
Monica Motwani, Ph.D., Laboratory Head for Oncology Biomarkers, Biomarkers
Development, Novartis Pharmaceuticals
|
|
|
|
|
|
Circulating Tumor Cells expressing IGF-1R: Method of Detection, Incidence and Potential Applications in the Development of IGF-1R Targeted
Therapy
Candace Fuchs, Clinical Oncology Biomarker Clinician, Pfizer
|
|
